NO20044156L - Nye 1,2,3-substituerte indolizinderivater, inhibitorer av FGF`er, fremgangsmate for fremstilling av de samme, og farmasoytiske preparater inneholdende de samme - Google Patents

Nye 1,2,3-substituerte indolizinderivater, inhibitorer av FGF`er, fremgangsmate for fremstilling av de samme, og farmasoytiske preparater inneholdende de samme

Info

Publication number
NO20044156L
NO20044156L NO20044156A NO20044156A NO20044156L NO 20044156 L NO20044156 L NO 20044156L NO 20044156 A NO20044156 A NO 20044156A NO 20044156 A NO20044156 A NO 20044156A NO 20044156 L NO20044156 L NO 20044156L
Authority
NO
Norway
Prior art keywords
same
fgfs
inhibitors
processes
preparation
Prior art date
Application number
NO20044156A
Other languages
English (en)
Other versions
NO329025B1 (no
Inventor
Marie-Francoise Bordes
Jean-Marc Herbert
Alain Badorc
Francoise Bono
Nathalie Guillo
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of NO20044156L publication Critical patent/NO20044156L/no
Publication of NO329025B1 publication Critical patent/NO329025B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
NO20044156A 2002-04-04 2004-09-30 Nye 1,2,3-substituerte indolizinderivater, fremgangsmate for fremstilling av de samme, og farmasoytiske preparater inneholdende de samme NO329025B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0204220A FR2838123B1 (fr) 2002-04-04 2002-04-04 Nouveaux derives d'indolozine-1,2,3 substituee, inhibiteurs selectifs du b-fgf
PCT/FR2003/001030 WO2003084956A1 (fr) 2002-04-04 2003-04-02 NOUVEAUX DERIVES D'INDOLIZINE 1,2,3 SUBSTITUEE, INHIBITEURS DES FGFs, LEUR PROCEDE DE PREPARATION ET LES COMPOSITIONS PHARMACEUTIQUES LES CONTENANT

Publications (2)

Publication Number Publication Date
NO20044156L true NO20044156L (no) 2005-01-03
NO329025B1 NO329025B1 (no) 2010-08-02

Family

ID=28052118

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20044156A NO329025B1 (no) 2002-04-04 2004-09-30 Nye 1,2,3-substituerte indolizinderivater, fremgangsmate for fremstilling av de samme, og farmasoytiske preparater inneholdende de samme

Country Status (34)

Country Link
US (2) US7442708B2 (no)
EP (1) EP1495023B1 (no)
JP (1) JP4741799B2 (no)
KR (1) KR101022138B1 (no)
CN (1) CN100413863C (no)
AR (1) AR040404A1 (no)
AT (1) ATE304013T1 (no)
AU (1) AU2003240984B2 (no)
BR (1) BR0309026A (no)
CA (1) CA2476056C (no)
CO (1) CO5631442A2 (no)
DE (1) DE60301570T2 (no)
DK (1) DK1495023T3 (no)
EA (1) EA007902B1 (no)
EC (1) ECSP045338A (no)
ES (1) ES2247540T3 (no)
FR (1) FR2838123B1 (no)
HK (1) HK1074631A1 (no)
HR (1) HRP20040912B1 (no)
IL (2) IL163755A0 (no)
IS (1) IS2475B (no)
MA (1) MA27297A1 (no)
ME (2) MEP22508A (no)
MX (1) MXPA04009639A (no)
NO (1) NO329025B1 (no)
NZ (1) NZ534786A (no)
PL (1) PL215265B1 (no)
RS (1) RS51399B (no)
SI (1) SI1495023T1 (no)
TN (1) TNSN04188A1 (no)
TW (1) TWI335222B (no)
UA (1) UA78016C2 (no)
WO (1) WO2003084956A1 (no)
ZA (1) ZA200406613B (no)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2859997B1 (fr) * 2003-09-18 2006-02-03 Sanofi Synthelabo Nouveaux derives d'indolizine 1,2,3,6,7,8 substituee, inhibiteurs des fgfs, leur procede de preparation et les compositions pharmaceutiques les contenant.
KR101279748B1 (ko) * 2003-11-04 2013-07-04 가부시키가이샤 디나벡크 겐큐쇼 유전자 도입된 수상세포의 제조방법
FR2865934B1 (fr) * 2004-02-05 2006-05-05 Sanofi Synthelabo Utilisation de derives d'indolizine 1,2,3 substitues, inhibiteurs des fgfs, pour la preparation de medicaments utiles pour le traitement de maladies liees a une angiogenese pathologique choroidienne
JP5296983B2 (ja) 2004-06-24 2013-09-25 株式会社ディナベック研究所 Ｒｎａウイルスが導入された樹状細胞を含む抗癌剤
MX2007006102A (es) * 2004-11-22 2007-07-11 Threshold Pharmaceuticals Inc Agentes anti-cancer de union a tubulina y profarmacos de los mismos.
FR2883286B1 (fr) 2005-03-16 2008-10-03 Sanofi Aventis Sa NOUVEAUX DERIVES D'IMIDAZO[1,5-a]PYRIDINES, INHIBITEURS DE FGFs, LEUR PROCEDE DE PREPARATION ET LES COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
FR2896247B1 (fr) * 2006-01-13 2008-02-29 Sanofi Aventis Sa Composes dimeres agonistes des recepteurs des fgfs (fgfrs), leur procede de preparation et leur application en therapeutique
EP1891955A1 (en) * 2006-07-24 2008-02-27 Sanofi-Aventis Use of 1,2,3-substituted indolizine derivatives, inhibitors of FGFs, for the preparation of a medicament intended for the treatment of degenerative joint diseases
WO2010027762A1 (en) * 2008-09-04 2010-03-11 Boehringer Ingelheim International Gmbh Indolizine inhibitors of leukotriene production
WO2010108503A1 (en) 2009-03-24 2010-09-30 Life & Brain Gmbh Promotion of neuronal integration in neural stem cell grafts
EP2270043A1 (en) * 2009-07-03 2011-01-05 Sanofi-Aventis Extracellular allosteric inhibitor binding domain from a tyrosine kinase receptor
CN101648953B (zh) * 2009-09-24 2012-09-05 绍兴文理学院 一种咪唑并[1，2-b]吡咯并[1，2-f]哒嗪衍生物及其制备方法和用途
FR2962437B1 (fr) * 2010-07-06 2012-08-17 Sanofi Aventis Derives d'imidazopyridine, leur procede de preparation et leur application en therapeutique
FR2962438B1 (fr) * 2010-07-06 2012-08-17 Sanofi Aventis Derives d'indolizines, procedes de preparation et application en therapeutique
FR2967412B1 (fr) * 2010-11-17 2012-12-14 Sanofi Aventis Nouveaux derives d'indolizine, leur preparation et leur application en therapeutique
FR2985258A1 (fr) * 2011-12-28 2013-07-05 Sanofi Sa Composes dimeres agonistes des recepteurs des fgfs (fgfrs), leur procede de preparation et leur application en therapeutique
AU2015362422B2 (en) * 2014-12-10 2019-11-14 Ono Pharmaceutical Co., Ltd. Dihydroindolizinone derivative
EP3318563A1 (en) * 2016-11-07 2018-05-09 Sanofi Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders
CN108864083B (zh) * 2018-06-07 2021-05-25 广东药科大学 一类具有抗癌活性的氨基取代吲嗪类化合物及其衍生物
CN110251513A (zh) * 2019-07-03 2019-09-20 南京大学 一种含吡唑的中氮茚化合物在制备抗肿瘤药物中的应用
US11976066B1 (en) 2023-10-23 2024-05-07 King Faisal University Substituted 7-amino-3-(substituted benzoyl)indolizine-1-carboxylates as anti-tubercular agents

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ193926A (en) * 1979-07-06 1984-05-31 Labaz Sanofi Nv 2-(alkyl or phenyl)-3(4-hydroxybenzoyl)indolizines
US4378362A (en) * 1979-12-06 1983-03-29 S.A. Labaz N.V. Indolizine derivatives and process for preparing the same
FR2528845A1 (fr) * 1982-06-17 1983-12-23 Sanofi Sa Nouveaux derives d'indolizine, leur procede de preparation ainsi que les compositions therapeutiques les contenant
FR2594438B1 (fr) * 1986-02-14 1990-01-26 Labaz Sanofi Nv Derives d'indolizine, leur procede de preparation ainsi que les compositions en contenant
GB9318790D0 (en) * 1993-09-10 1993-10-27 Fujisawa Pharmaceutical Co Heterocyclic derivatives
WO2000071129A1 (en) * 1999-05-21 2000-11-30 Bristol-Myers Squibb Company Pyrrolotriazine inhibitors of kinases
DE60213802T2 (de) * 2001-06-06 2007-03-29 Vertex Pharmaceuticals Inc., Cambridge Cak inhibitoren und deren verwendungen
FR2859997B1 (fr) * 2003-09-18 2006-02-03 Sanofi Synthelabo Nouveaux derives d'indolizine 1,2,3,6,7,8 substituee, inhibiteurs des fgfs, leur procede de preparation et les compositions pharmaceutiques les contenant.

Also Published As

Publication number Publication date
CA2476056A1 (fr) 2003-10-16
CA2476056C (fr) 2012-03-06
RS86404A (en) 2006-12-15
ECSP045338A (es) 2005-03-10
EP1495023B1 (fr) 2005-09-07
IL163755A (en) 2010-11-30
EP1495023A1 (fr) 2005-01-12
TWI335222B (en) 2011-01-01
PL215265B1 (pl) 2013-11-29
TNSN04188A1 (fr) 2007-03-12
ES2247540T3 (es) 2006-03-01
RS51399B (en) 2011-02-28
EA007902B1 (ru) 2007-02-27
JP2005532286A (ja) 2005-10-27
HK1074631A1 (en) 2005-11-18
ME00118B (me) 2010-10-10
DK1495023T3 (da) 2005-12-27
MEP22508A (en) 2010-06-10
CN100413863C (zh) 2008-08-27
AU2003240984A1 (en) 2003-10-20
CO5631442A2 (es) 2006-04-28
KR20040099388A (ko) 2004-11-26
DE60301570D1 (de) 2005-10-13
US20050203126A1 (en) 2005-09-15
HRP20040912A2 (en) 2004-12-31
KR101022138B1 (ko) 2011-03-17
MA27297A1 (fr) 2005-05-02
TW200306181A (en) 2003-11-16
SI1495023T1 (sl) 2005-12-31
MXPA04009639A (es) 2005-07-13
DE60301570T2 (de) 2006-05-18
JP4741799B2 (ja) 2011-08-10
IS2475B (is) 2008-12-15
AR040404A1 (es) 2005-04-06
PL372812A1 (en) 2005-08-08
US7803811B2 (en) 2010-09-28
ATE304013T1 (de) 2005-09-15
NO329025B1 (no) 2010-08-02
HRP20040912B1 (hr) 2012-10-31
ZA200406613B (en) 2007-12-27
NZ534786A (en) 2006-06-30
IL163755A0 (en) 2005-12-18
UA78016C2 (uk) 2007-02-15
AU2003240984B2 (en) 2008-07-31
BR0309026A (pt) 2005-02-09
US7442708B2 (en) 2008-10-28
WO2003084956A1 (fr) 2003-10-16
CN1649867A (zh) 2005-08-03
FR2838123A1 (fr) 2003-10-10
EA200400994A1 (ru) 2005-06-30
FR2838123B1 (fr) 2005-06-10
US20090023770A1 (en) 2009-01-22
IS7413A (is) 2004-08-19

Similar Documents

Publication Publication Date Title
NO20044156L (no) Nye 1,2,3-substituerte indolizinderivater, inhibitorer av FGF`er, fremgangsmate for fremstilling av de samme, og farmasoytiske preparater inneholdende de samme
NO329884B1 (no) Indolderivater, farmasoytisk formulering, anvendelse av forbindelsene, fremgangsmate for fremstilling derav samt mellomprodukter for anvendelse i fremgangsmaten
HUP0104204A3 (en) Pyrazolopyridine derivatives as cox-2 inhibitors, process for their preparation and pharmaceutical compositions thereof
HUP0401503A3 (en) Indole, azaindole and related heterocyclic aminopiperazine derivatives and pharmaceutical compositions containing them
LTPA2014005I1 (lt) Chinazolidino dariniai, minėtus junginius turintys vaistai, jų panaudojimas ir jų gavimo būdas
IL161431A0 (en) beta-PHENYL-alpha-OXYSUBSTITUTED PROPIONIC ACID DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
NO20014013L (no) 16-halogen-epotilonderivater, fremgangsmåter for fremstilling av disse og farmasöytisk anvendelse av dem
HUP0200895A3 (en) Benzimidazole derivatives of alpha-substituted carboxylic acids, pharmaceutical compositions containing them and their use
DK1202965T3 (da) Indolderivater, fremgangsmåde til fremstilling deraf, farmaceutiske præparater indeholdende disse og deres medicinske anvendelse
EE04275B1 (et) Kinoliini derivaadid, nende valmistamismeetodid, kasutamine ja farmatseutilised kompositsioonid
HK1084123A1 (en) Novel fluoroglycoside heterocyclic derivatives, pharmaceutical products containing said compounds and the use thereof
NO20013736D0 (no) Pyrazolkarboksylsyrederivater, deres fremstilling og farmasöytiske preparater inneholdende de samme
IL165200A0 (en) Indole, azaindole and heterocyclic 4-alkenyl piperadine amide derivatives and pharmaceutical compositions containing the same
NO20040268L (no) Nye 2H-pyridazin-3-derivater, farmasoytiske preparater inneholdende slike og fremgangsmate for fremstilling av den aktive ingrediensen
HUP0400200A3 (en) Pharmaceutical formulation for the efficient administration of apomorphine, 6ar-(-)-n-propyl-norapomorphine and their derivatives and pro-drugs thereof
AU2002233463A1 (en) Urea derivatives, method for preparing same, use thereof as medicines, pharmaceutical compositions and use
IL140525A0 (en) 2-aminopyridine derivatives, their use as medicines and pharmaceutical compositions containing them
PL347105A1 (en) Propanolamine derivatives substituted with heterocyclic compounds, methods for their production, pharmaceutical compositions containing said compounds and the use thereof
NO326689B1 (no) Pyrrolidinderivater, anvendelse derav, farmasøytisk preparat samt fremgangsmåte for fremstilling av forbindelsene
HUP0400317A3 (en) Beta-carboline derivatives, process for their preparation, their use and pharmaceutical compositions containing them
IS2199B (is) Svæfandi ß-karbólín afleiður, aðferð til framleiðslu þeirra og notkun þeirra sem læknislyf
NO20016404L (no) Naftyridinderivater, fremgangsmåter for deres fremstilling, deres anvendelse og farmasöytiske preparater omfattende disse
NO20013878L (no) (1-fenacy-3-fenyl-3-piperidylety)piperidinderivater, fremgangsmåte for fremstilling derav og farmasöytiske preparaterinneholdende de samme
NO20042022L (no) Fast legemiddelformulering som inneholder pipiperazinurea-derivat og fremgangsmate for fremstilling av formuleringen
NO20034985D0 (no) Nye 5-tio-SS-D-xylopyranosid-derivater, fremgangsmåte for fremstilling derav, farmasöytiske blandinger inneholdende dem og den terapeutiskeanvendelse derav

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees